142.92 0.00 (0.00%)
After hours: 4:36PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||141.22 - 144.50|
|52 Week Range||133.82 - 178.86|
|PE Ratio (TTM)||6.29|
|Forward Dividend & Yield||1.36 (0.89%)|
|1y Target Est||N/A|
Depomed (DEPO) has adopted a three-pronged business strategy with three key elements: maintain, build, and grow. Depomed aims to maintain its Nucynta franchise of pain products through the commercialization agreement it entered into with Collegium Pharmaceutical in December 2017. Under this agreement, Depomed granted commercialization rights for the Nucynta franchise of pain products to Collegium Pharmaceutical in the US.
After months of inaction by the federal government on the crisis regarding opioid abuse, Attorney General Jeff Sessions announced the creation of a task force charged with looking at how drug makers and ...
WASHINGTON (AP) — The Justice Department said Tuesday it will support local officials in hundreds of lawsuits against manufacturers and distributors of powerful opioid painkillers that are fueling the nation's drug abuse crisis.
AmerisourceBergen must enact sweeping reforms that address its role in the opioid crisis, says Teamsters' Treasurer Ken Hall.
Ohio on Monday accused four major pharmaceutical distributors of ignoring their responsibilities to ensure that opioids were not being diverted for improper uses, contributing to a drug abuse epidemic ...
Pharmaceutical distributors enjoy a competitive advantage that’s tough to crack, writes Vitaliy Katsenelson.
McKesson and Cardinal Health are alleged to have sent more than 12 million opioid doses to a single pharmacy in West Virginia over an eight-year period, according to a House committee probe.
A possible Walgreens buy of AmerisourceBergen as well as the latest Amazon rumor threaten to upend drug and medical supplies distribution.
Shares of health-care distributors fell Tuesday on news the sector could experience more consolidation and heightened competition from retail giant Amazon.com Inc.
Moody's Investors Service ("Moody's") assigned a Baa2 rating to McKesson Corporation's (McKesson) new Euro and US note offerings. All of McKesson's existing note and short term ratings remain ...
In front of financiers and other potential investors at last month's J.P. Morgan Healthcare Conference, McKesson Corp. CEO John Hammergren highlighted the company's distribution of so-called "destruction pouches" as a way of taking unused opioid painkillers out of circulation. Along with a national, real-time network identifying potential misused prescriptions, the drug deactivation pouches are one of the ways that San Francisco-based McKesson (MCK) — one of the big three medical distributors nationally — says it is fighting an opioid crisis that has pulled the company into 192 legal complaints and killed tens of thousands of people. "We're exploring those (pouches) in different markets," Hammergren said.
The Zacks Analyst Blog Highlights: Lockheed Martin, Mastercard, Colgate, Electronic Arts and McKesson
On this week's episode of CTRL+T, it's all about flamethrowers (yes, the devices that throw flames), startups trying to get inside your mouth and education in the prison system.
Keith Bliss of Cuttone and Company joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to break down the latest market action.